Olga Piątek-Dalewska

Olga Piątek-Dalewska


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
Patryk PoniewierzaPatryk Poniewierza
Patryk Poniewierza
Marcin ŚniadeckiMarcin Śniadecki
Marcin Śniadecki
OMOliwia Musielak
Oliwia Musielak
Afsheen RazaAfsheen Raza
Afsheen Raza
YSYousra Safari
Yousra Safari
DWDariusz Wydra
Dariusz Wydra
Background/Objectives: Cervical cancer is the second most common gynecological cancer worldwide, preventable through screening initiatives and vaccinations against its causative agent, anogenital human papillomavirus (HPV). This study aimed at measuring the coverage and uptake of the national HPV vaccination program launched in 2023 and implemented throughout Poland. Methods: This cross-sectional, observational study analyzed population data of adolescents in 11–13-year-old groups vaccinated in individual voivodeships (provinces) of Poland as provided by the National Health Fund and the Central Statistical Office. A p-value of <0.05 was considered statistically significant. Results: The rate of HPV vaccination participation under the population program was 8.67%. In the analyzed age groups, in both sexes, no statistically significant correlation was observed between the population size at a given age and population coverage or participation in HPV vaccination. However, a positive relationship in vaccination coverage was observed in individuals previously vaccinated with one dose in subsequent age groups, indicating a continued willingness to receive vaccination with further doses. No statistically significant difference in population coverage changes across voivodeships was found between the number of doses within the urban population share vs. rural population share. Conclusions: Our results show that, at 1.5 years of implementation of the national HPV vaccination program, the coverage and uptake of the program is considerably insufficient. The intensive corrective actions indicated are required to pave this program forward towards optimum results.

26 March 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
Marcin ŚniadeckiMarcin Śniadecki
Marcin Śniadecki
Benedetta GuaniBenedetta Guani
Benedetta Guani
PJPaulina Jaworek
Paulina Jaworek
DKDagmara Klasa-Mazurkiewicz
Dagmara Klasa-Mazurkiewicz
KMKatia Mahiou
Katia Mahiou
DWDariusz Wydra
Dariusz Wydra

25 February 2025 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
DPDamian Palus
Damian Palus
MGMartyna Gołębiewska
Martyna Gołębiewska
OPOlga Piątek-Dalewska
Olga Piątek-Dalewska
KGKrzysztof Grudziński
Krzysztof Grudziński
Krzysztof KuziemskiKrzysztof Kuziemski
Krzysztof Kuziemski
TSTomasz J Stefaniak
Tomasz J Stefaniak
Background: This study evaluates the impact of pre-existing comorbidities and in-hospital complications on COVID-19 mortality rates. Methods: A retrospective single-center study was conducted using electronic health records from 640 COVID-19 patients hospitalized at the University Clinical Centre in Gdansk, Poland, between November 2020 and May 2021. Patients were categorized based on disease severity into stable or ICU wards based on the disease severity. Data on demographics, comorbidities, complications, and treatments were collected and verified. Statistical analyses, including odds ratios (ORs) and confidence intervals (CIs), assessed mortality risk factors supported by python-based processing. Results: The mean patient age was 67 years (SD ± 15.89), comprising 39% females (n = 250) and 60.94% males (n = 390). Mortality risk was highest in patients aged 65 years and older (OR 3.00; 95% CI, 1.97–4.60). Among the pre-existing comorbidities, chronic kidney disease (OR 3.28; 95% CI, 2.12–5.09), atrial fibrillation (OR 2.43; CI 95%, 1.63–3.61), and heart failure (OR 2.89; 95% CI, 1.91–4.37) were significant predictors of mortality. In hospital complications, such as severe respiratory failure requiring ICU ventilation (OR 23.59; 95% CI, 2.81–197.87), myocardial infarction (OR 25.43; 95% CI, 3.16–204.97), acute kidney injury requiring renal replacement therapy (OR 19.15; 95% CI, 6.49–56.51), sepsis (OR 7.22, 95% CI, 3.77–13.84), stroke, further increased mortality risk. Conclusions: COVID-19 patients with pre-existing renal and cardiovascular conditions face a higher risk of fatal outcomes. Early diagnosis and intervention targeting these complications are vital to in reducing mortality. Further research is needed to reconcile disparities with existing literature. Keywords: COVID-19 complications SARS-CoV-2 comorbidity in-hospital mortality risk factors

18 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Marcin ŚniadeckiMarcin Śniadecki
Marcin Śniadecki
MDMartyna Maja Danielkiewicz
Martyna Maja Danielkiewicz
OPOlga Piątek-Dalewska
Olga Piątek-Dalewska
PJPaulina Jaworek
Paulina Jaworek
Vincent BALAYAVincent BALAYA
Vincent BALAYA
DWDariusz Wydra
Dariusz Wydra
Background: Cervical cancer lymph node metastasis involves lymphovascular space invasion (LVSI), isolated tumor cells (ITC), and micro- and macro-metastases (MIC and MAC), all potential targets for prevention and treatment. Purpose: This study aimed to track cancer spread, identify risk factors for lymph node metastasis, and explore avenues for prevention. Methods: We conducted a retrospective analysis on 27 early cervical cancer patients (tumor size ≤ 4 cm) who underwent sentinel (SLN) and non-sentinel (nSLN) lymph node dissection and histopathological ultrastaging. Patient and tumor characteristics associated with lymph node events (LNE) and prevention efforts were analyzed, following STROBE guidelines. Results: Primary prevention steps were absent, secondary prevention was limited to opportunistic measures, and follow-up served as tertiary prevention. LNE occurred in 11 of 27 cases: 4 with ITC alone, 1 with MIC alone, 1 with both ITC and MIC, 1 with MAC alone, and 4 with both MIC and MAC. Obturator and external iliac lymph nodes were most commonly affected, and only LVSI was a significant predictor of LNE (p < 0.05). Among LNE cases, 9 patients were at FIGO stage 1b1 and 2 at stage 1b2. The smallest tumor with lymph node burden (ITC in both SLN and nSLN) was 2.0 cm, while MAC alone occurred in a single nSLN case. Conclusions: Limited prevention at all levels contributes to lymph node metastasis in about half of early-stage cervical cancer cases. FIGO stages do not adequately predict the extent, type, or distribution of lymph node invasion.

12 December 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
OPOlga Piątek-Dalewska
Olga Piątek-Dalewska
Krzysztof KuziemskiKrzysztof Kuziemski
Krzysztof Kuziemski
PGPeter Grešner
Peter Grešner
ZAZielińska Alicja
Zielińska Alicja
TSTomasz J Stefaniak
Tomasz J Stefaniak
DPDamian Palus
Damian Palus
Solid organ transplant recipients were among the most vulnerable groups during the COVID-19 pandemic. Chronic immunosuppression and multiple comorbidities

9 July 2022 in medRxiv
Verified
Preprint
Open access
PDF file
DPDamian Palus
Damian Palus
MGMartyna Gołębiewska
Martyna Gołębiewska
OPOlga Piątek-Dalewska
Olga Piątek-Dalewska
AMAlan Majeranowski
Alan Majeranowski
Radoslaw OwczukRadoslaw Owczuk
Radoslaw Owczuk
TSTomasz J Stefaniak
Tomasz J Stefaniak
Introduction: Presenting outcomes of patients hospitalised for coronavirus disease (COVID-19) should be put in context and comparison with other facilities. Number of statistical parameters can be used to compare effectiveness of treatment, however varied methodology applied in studies can impede or hinder a reliable comparison. The aim of this study is to present outcomes of COVID-19 treatment in our facility using simplest parameters allowing for intercenter comparison - case fatality ratio (CFR), length of stay (LOS) and transparent patients’ characteristics, and to discuss factors affecting mortality in COVID-19. Methods: The data were collected from patients hospitalized in COVID-19 general and ICU isolation wards in the University Clinical Centre (UCC) in Gdansk, Poland, from November 2020 to June 2021, using a computer-based patient record system. The group consisted of 642 patients – 144 (39,1 %) were women and 391 (60,9 %) were men, with a median age of 69 (IQR 59-78) years. Values of LOS and CFR were calculated and analysed. Results: Overall CFR for the analysed period was 24,8 %, varying from 19,9 % in January to May 2021 to 33,8 % in November to December 2020. CFR was 18,9 % in general ward and 70,7 % in ICU. All ICU patients required intubation and mechanical ventilation, and forty-four (75,9 %) of them developed acute respiratory distress syndrome (ARDS). Average length of stay was 13,1 (± 7,1) days. Conclusion: CFR in the general ward in UCC was analogous to published outcomes, but higher in our ICU ward. It resulted from more rigorous ICU admittance criteria in UCC compared to other facilities, which corresponds with patients’ severe clinical condition and unfavourable prognosis. Heterogeneity of methods assessing initial clinical condition in different facilities makes a meaningful intercenter comparison challenging. In this study, we propose simple and transparent statistical and clinical parameters applicable in an intercenter analysis. What is already known on this topic - the outbreak of global pandemic caused by novel coronavirus SARS-CoV-2 has strained healthcare systems all over the world. Healthcare workers faced new challenges, as organisational, structural, and personal flaws were unearthed in the process. In subsequent waves the number of hospitalisations increased together with the death number in the ICUs. As we come to terms with a new disease, numerous studies reports, analyse and assess COVID-19 treatment outcomes What this study adds - COVID-19 treatment outcomes in ICU in our facility contrast with most of the published reports. We analyse the influence of some commonly omitted under-examined factors and propose simple and applicable parameters to compare results, such as CFR and LOS, enabling a meaningful intercenter comparison. How this study might affect research, practice, or policy - inclusion of CFR and LOS in studies on COVID-19 would remove significant bias and enable more robust evaluation of therapeutic interventions and outcomes. In this study we also discuss heterogeneity of admission criteria and show how their influence on treatment outcomes.